Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

5-OH-DPAT

From Wikipedia, the free encyclopedia
Dopamine receptor agonist compound
5-OH-DPAT
Stereo, Kekulé, skeletal formula of (S)-5-OH-DPAT
Stereo, Kekulé, skeletal formula of (S)-5-OH-DPAT
Names
Preferred IUPAC name
(6S)-6-(Dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol
Identifiers
3D model (JSmol)
Abbreviations5-OH-DPAT
ChEMBL
ChemSpider
MeSH5-Hydroxy-2-N,N-dipropylaminotetralin
  • InChI=1S/C16H25NO/c1-3-10-17(11-4-2)14-8-9-15-13(12-14)6-5-7-16(15)18/h5-7,14,18H,3-4,8-12H2,1-2H3/t14-/m0/s1 checkY
    Key: MDBWEQVKJDMEMK-AWEZNQCLSA-N checkY
  • Oc1cccc2c1CC[C@H](N(CCC)CCC)C2
  • CCCN(CCC)C1CCc2c(O)cccc2C1
  • CCCN(CCC)C1CCC2=C(O)C=CC=C2C1
Properties
C16H25NO
Molar mass247.382 g·mol−1
logP3.55
Acidity (pKa)10.543
Basicity (pKb)3.454
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)
Chemical compound

5-OH-DPAT is a synthetic compound that acts as adopamine receptoragonist with selectivity for theD2 receptor andD3 receptor subtypes.[1][2] Only the (S)-enantiomer is active as an agonist, with the (R)-enantiomer being a weak antagonist at D2 receptors.[3]Radiolabelled11C-5-OH-DPAT is used as an agonist radioligand for mapping the distribution and function of D2 and D3 receptors in the brain,[4][5] and the drug is also being studied in the treatment ofParkinson's disease.[6][needs update]

See also

[edit]

References

[edit]
  1. ^Seiler MP, Stoll AP, Closse A, Frick W, Jaton A, Vigouret JM (June 1986). "Structure-activity relationships of dopaminergic 5-hydroxy-2-aminotetralin derivatives with functionalized N-alkyl substituents".Journal of Medicinal Chemistry.29 (6):912–7.doi:10.1021/jm00156a007.PMID 3712381.
  2. ^Johansson AM, Nilsson JL, Karlén A, Hacksell U, Svensson K, Carlsson A, Kenne L, Sundell S (July 1987). "C3-methylated 5-hydroxy-2-(dipropylamino)tetralins: conformational and steric parameters of importance for central dopamine receptor activation".Journal of Medicinal Chemistry.30 (7):1135–44.doi:10.1021/jm00390a004.PMID 3599021.
  3. ^Karlsson A, Björk L, Pettersson C, Andén NE, Hacksell U (1990). "(R)- and (S)-5-hydroxy-2-(dipropylamino)tetralin (5-OH DPAT): assessment of optical purities and dopaminergic activities".Chirality.2 (2):90–5.doi:10.1002/chir.530020206.PMID 1976017.
  4. ^Mukherjee J, Narayanan TK, Christian BT, Shi B, Dunigan KA, Mantil J (July 2000)."In vitro and in vivo evaluation of the binding of the dopamine D2 receptor agonist (11)C-(R,S)-5-hydroxy-2-(di-n-propylamino)tetralin in rodents and nonhuman primate".Synapse (New York, N.Y.).37 (1):64–70.doi:10.1002/(SICI)1098-2396(200007)37:1<64::AID-SYN7>3.0.CO;2-F.PMID 10842352.S2CID 43878278.
  5. ^Leung K (2006). "(R,S)-2-(N-Propyl-N-1'-[11C]-propyl)amino-5-hydroxytetralin".Molecular Imaging and Contrast Agent Database.PMID 20641325.
  6. ^Ackaert OW, Graan JD, Shi S, Vreeken R, Della Pasqua OE, Dijkstra D, Westerink BH, Danhof M, Bouwstra JA (January 2011). "The pharmacokinetics and pharmacological effect of (S)-5-OH-DPAT following controlled delivery with transdermal iontophoresis".Journal of Pharmaceutical Sciences.100 (7):2996–3009.doi:10.1002/jps.22492.PMID 21283984.
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
Stub icon

Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it.

Stub icon

This article about anorganic compound is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=5-OH-DPAT&oldid=1283129092"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp